查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
藥物發現服務市場：2019-2029 年全球市場規模、佔有率、趨勢分析、機遇和預測報告
市場調查報告書
商品編碼
1301796

藥物發現服務市場：2019-2029 年全球市場規模、佔有率、趨勢分析、機遇和預測報告

Drug Discovery Services Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type ; By Process ; By Drug Type ; By Therapeutic Area ; By End User ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

到 2029 年，全球藥物發現服務市場將成長 2.8 倍，達到 530 億美元

由於製藥和生物技術公司研發投資的增加、藥物發現複雜性的增加、慢性病患病率的增加以及政府努力簡化和加快藥物開發和審批流程，全球藥物發現服務市場正在蓬勃發展。

領先的戰略諮詢和市場研究公司 BlueWeave Consulting 最近估計，2022 年全球藥物發現服務市場價值將達到 185 億美元。 BlueWeave預測，在2023-2029年的預測期內，全球藥物發現服務市場規模將以15.2%的年複合成長率成長，到2029年達到528億美元。疾病日益複雜以及對個性化醫療的需求使得新藥發現變得更具挑戰性。這種複雜性需要多學科方法和專業知識，這可以通過外包獲得。製藥和生物技術公司大力投資研發活動，以發現新藥和治療方法。外包藥物發現過程的某些階段可以更有效地利用專業知識和資源。此外，製藥公司、學術機構和 CRO 之間的合作夥伴關係在藥物發現領域變得越來越普遍。這種夥伴關係促進知識共享、專業知識的獲取和資源共享，從而促進創新並推動市場成長。

該報告的詳細分析提供了有關全球藥物發現服務市場的成長潛力、未來趨勢和統計數據的資訊。它還重點關注推動市場總規模預測的因素。該報告提供了全球藥物發現服務市場的最新技術發展以及行業見解，以幫助決策者做出明智的戰略決策。它還分析了市場的成長促進因素、挑戰和競爭力。

目錄

第1章 研究框架

第2章 執行摘要

第3章 全球藥物發現服務市場洞察

  • 行業價值鏈分析
  • DROC分析
    • 成長動力
      • 慢性病患病率
      • 藥物發現活動外包
      • 研發費用增加
    • 抑制因素
      • 嚴格的監管要求
      • 故障率高
    • 機會
      • 個性化醫療的出現
      • 越來越關注孤兒疾病和孤兒藥物
    • 任務
      • 道德問題和公眾認知
  • 技術進步/最新發展
  • 監管框架
  • 波特五力分析
  • 全球藥物發現服務市場概況
  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
      • 化學服務
      • 生物服務
    • 按流程
      • 目標驗證
      • 目標選擇
      • H2L的識別
      • 候選人驗證
      • 潛在客戶最佳化
    • 按藥物類型
      • 生物製劑
      • 小分子藥物
    • 按治療領域
      • 神經病學
      • 傳染病和免疫系統疾病
      • 消化系統疾病
      • 瘤
      • 其他
    • 按最終用戶
      • 製藥和生物技術公司
      • 學術機構
      • 其他
    • 按地區
      • 北美
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第4章 北美藥物發現服務市場

    • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按流程
    • 按藥物類型
    • 按治療領域
    • 按最終用戶
    • 按國家/地區
      • 美國
      • 按類型
      • 按流程
      • 按藥物類型
      • 按治療領域
      • 按最終用戶
      • 加拿大
      • 按類型
      • 按流程
      • 按藥物類型
      • 按治療領域
      • 按最終用戶

第5章 歐洲藥物發現服務市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按流程
    • 按藥物類型
    • 按治療領域
    • 按最終用戶
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第6章 亞太藥物發現服務市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按流程
    • 按藥物類型
    • 按治療領域
    • 按最終用戶
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳大利亞和紐西蘭
      • 印度尼西亞
      • 馬來西亞
      • 新加坡
      • 越南
      • 亞太地區其他國家

第7章 拉丁美洲藥物發現服務市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按流程
    • 按藥物類型
    • 按治療領域
    • 按最終用戶
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲

第8章 中東和非洲藥物發現服務市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按流程
    • 按藥物類型
    • 按治療領域
    • 按最終用戶
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • MEA 的其餘部分

第9章 競爭格局

  • 主要公司及其產品列表
  • 2022年全球藥物發現服務企業市場佔有率分析
  • 通過運行參數進行競爭基準測試
  • 主要戰略發展（合併、收購、合作）

第10章 COVID-19 對全球藥物發現服務市場的影響

第11章公司簡介（公司簡介、財務矩陣、競爭格局、關鍵人才、主要競爭、聯繫地址、戰略展望、SWOT分析）

  • General Electric
  • Eurofins Scientific
  • Syngene International Limited
  • Wuxi AppTec
  • Frontage Labs
  • Domainex
  • WIL Research Laboratories LLC
  • Shanghai Medicilon, Inc.
  • Labcorp Drug Development
  • Jubilant Biosys Ltd.
  • Evotec
  • Shanghai ChemPartner
  • Charles River Laboratories
  • Merck & Co. Inc.
  • Thermo Fisher Scientific Inc.
  • Other Prominent Players

第12章主要戰略建議

第13章調查方法

簡介目錄
Product Code: BWC23487

Global Drug Discovery Services Market Zooming 2.8X to Reach USD 53 Billion by 2029

Global drug discovery services market is booming due to the increasing R&D investments by pharmaceutical companies and biotechnology firms, complexity of drug discovery, increasing prevalence of chronic diseases, and government initiatives to streamline and expedite the drug development and approval process.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global drug discovery services market size at USD 18.5 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global drug discovery services market size to grow at a CAGR of 15.2% reaching a value of USD 52.8 billion by 2029. The discovery of new drugs has become more challenging due to the complexity of diseases and the need for personalized medicine. This complexity requires a multidisciplinary approach and specialized expertise, which can be obtained through outsourcing. Pharmaceutical companies and biotechnology firms are investing heavily in research and development activities to discover new drugs and therapies. Outsourcing certain stages of the drug discovery process allows them to access specialized expertise and resources more efficiently. Furthermore, collaborative partnerships between pharmaceutical companies, academic institutions, and CROs have become increasingly common in drug discovery. These partnerships facilitate knowledge sharing, access to specialized expertise, and resource pooling, fostering innovation and driving market growth.

Opportunity: Increasing Focus on Drug Research and Development

The pursuit of innovative and effective therapeutics is driving the pharmaceutical industry to allocate larger budgets towards R&D. As the global burden of diseases continues to rise, there is a growing demand for novel drugs that can address unmet medical needs. Pharmaceutical companies are motivated to invest more in R&D to discover breakthrough treatments, resulting in increased demand for drug discovery services. The advances in scientific knowledge and technologies have expanded the scope and complexity of drug discovery research. With the advent of genomics, proteomics, high-throughput screening, computational modelling, and other cutting-edge tools, the process of identifying and developing new drug candidates has become more intricate. These advancements require substantial investments in specialized equipment, expertise, and infrastructure, which in turn drive up R&D expenditures.

Impact of COVID-19 on the Drug Discovery Services Market

The COVID-19 pandemic had a profound impact on the drug discovery services market, affecting various aspects of the industry. The pandemic led to a heightened focus on infectious diseases. The urgent need for treatments and vaccines for COVID-19 drove significant investments and collaborations in research and development related to infectious diseases. Many drug discovery service providers redirected their efforts towards developing drugs and therapies specifically targeting the virus. This shift resulted in an increased demand for services related to target identification, lead optimization, and preclinical testing for infectious diseases. The limitations imposed by the pandemic accelerated the adoption of virtual screening and computational approaches in drug discovery. With physical laboratory work being restricted, drug discovery service providers increasingly relied on computer simulations, artificial intelligence, and machine learning algorithms to identify potential drug candidates. These technologies have played a crucial role in continuing research activities despite the limitations imposed by the pandemic. They enabled virtual collaborations, data analysis, and the identification of drug targets.

Global Drug Discovery Services Market - By Type:

Based on type, the global drug discovery services market is bifurcated into chemistry services and biology services segments. During the period in analysis, the chemistry services segment is expected to hold a significant market share due to the broad use of chemical services at various early stages of drug development to produce reliable drug candidates. The widespread use of chemistry in academia, biotechnology firms, and sizable pharmaceutical businesses also contributes to industry expansion.

Global Drug Discovery Services Market - By Process:

Based on process, the global drug discovery services market is segmented into target validation, target selection, hit-to-lead identification, candidate validation, and lead optimization. During the forecast period, Hit-To-Lead Identification is expected to hold a significant market share. Hit-To-Lead Identification is an early stage in the drug discovery process, where potential drug candidates, known as hits, are identified and further optimized into leads. As drug discovery efforts increase, there is a growing demand for services that focus on this crucial stage. The combination of specialized expertise, advanced screening technologies, computational approaches, and the ability to optimize hits into leads positions the Hit-To-Lead Identification segment as a significant player in the global drug discovery services market.

Competitive Landscape:

The drug discovery services market is fragmented, with numerous players serving the market. The key players dominating the global drug discovery services market include General Electric, Eurofins Scientific, Syngene International Limited, Wuxi AppTec, Frontage Labs, Domainex, WIL Research Laboratories LLC, Shanghai Medicilon, Inc., Labcorp Drug Development, Jubilant Biosys Ltd, Evotec, Shanghai ChemPartner, Charles River Laboratories, Merck & Co. Inc., Thermo Fisher Scientific Inc. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisition to expand their customer reach and gain a competitive edge in the overall market.

The report's in-depth analysis provides information about growth potential, upcoming trends, and the Global Drug Discovery Services Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Drug Discovery Services Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Drug Discovery Services Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Growing prevalence of chronic diseases
      • 3.2.1.2. Outsourcing of drug discovery activities
      • 3.2.1.3. Increasing R&D expenditure
    • 3.2.2. Restraints
      • 3.2.2.1. Stringent regulatory requirements
      • 3.2.2.2. High failure rates
    • 3.2.3. Opportunities
      • 3.2.3.1. Emergence of personalized medicine
      • 3.2.3.2. Increasing focus on rare diseases and orphan drugs
    • 3.2.4. Challenges
      • 3.2.4.1. Ethical concerns and public perception
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry
  • 3.6. Global Drug Discovery Services Market Overview
  • 3.7. Market Size & Forecast, 2019-2029
    • 3.7.1. By Value (USD Billion)
  • 3.8. Market Share & Forecast
    • 3.8.1. By Type
      • 3.8.1.1. Chemistry Services
      • 3.8.1.2. Biology Services
    • 3.8.2. By Process
      • 3.8.2.1. Target Validation
      • 3.8.2.2. Target Selection
      • 3.8.2.3. Hit-To-Lead Identification
      • 3.8.2.4. Candidate Validation
      • 3.8.2.5. Lead Optimization
    • 3.8.3. By Drug Type
      • 3.8.3.1. Biologics
      • 3.8.3.2. Small Molecule Drugs
    • 3.8.4. By Therapeutic Area
      • 3.8.4.1. Neurology
      • 3.8.4.2. Infectious & Immune System Diseases
      • 3.8.4.3. Digestive System Diseases
      • 3.8.4.4. Oncology
      • 3.8.4.5. Others
    • 3.8.5. By End User
      • 3.8.5.1. Pharmaceutical & Biotechnology Companies
      • 3.8.5.2. Academic Institutes
      • 3.8.5.3. Others
    • 3.8.6. By Region
      • 3.8.6.1. North America
      • 3.8.6.2. Europe
      • 3.8.6.3. Asia Pacific (APAC)
      • 3.8.6.4. Latin America (LATAM)
      • 3.8.6.5. Middle East and Africa (MEA)

4. North America Drug Discovery Services Market

    • 4.1.1. Market Size & Forecast, 2019-2029
    • 4.1.2. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type
    • 4.2.2. By Process
    • 4.2.3. By Drug Type
    • 4.2.4. By Therapeutic Area
    • 4.2.5. By End User
    • 4.2.6. By Country
      • 4.2.6.1. United States
      • 4.2.6.1.1. By Type
      • 4.2.6.1.2. By Process
      • 4.2.6.1.3. By Drug Type
      • 4.2.6.1.4. By Therapeutic Area
      • 4.2.6.1.5. By End User
      • 4.2.6.2. Canada
      • 4.2.6.2.1. By Type
      • 4.2.6.2.2. By Process
      • 4.2.6.2.3. By Drug Type
      • 4.2.6.2.4. By Therapeutic Area
      • 4.2.6.2.5. By End User

5. Europe Drug Discovery Services Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Process
    • 5.2.3. By Drug Type
    • 5.2.4. By Therapeutic Area
    • 5.2.5. By End User
    • 5.2.6. By Country
      • 5.2.6.1. Germany
      • 5.2.6.1.1. By Type
      • 5.2.6.1.2. By Process
      • 5.2.6.1.3. By Drug Type
      • 5.2.6.1.4. By Therapeutic Area
      • 5.2.6.1.5. By End User
      • 5.2.6.2. United Kingdom
      • 5.2.6.2.1. By Type
      • 5.2.6.2.2. By Process
      • 5.2.6.2.3. By Drug Type
      • 5.2.6.2.4. By Therapeutic Area
      • 5.2.6.2.5. By End User
      • 5.2.6.3. Italy
      • 5.2.6.3.1. By Type
      • 5.2.6.3.2. By Process
      • 5.2.6.3.3. By Drug Type
      • 5.2.6.3.4. By Therapeutic Area
      • 5.2.6.3.5. By End User
      • 5.2.6.4. France
      • 5.2.6.4.1. By Type
      • 5.2.6.4.2. By Process
      • 5.2.6.4.3. By Drug Type
      • 5.2.6.4.4. By Therapeutic Area
      • 5.2.6.4.5. By End User
      • 5.2.6.5. Spain
      • 5.2.6.5.1. By Type
      • 5.2.6.5.2. By Process
      • 5.2.6.5.3. By Drug Type
      • 5.2.6.5.4. By Therapeutic Area
      • 5.2.6.5.5. By End User
      • 5.2.6.6. Belgium
      • 5.2.6.6.1. By Type
      • 5.2.6.6.2. By Process
      • 5.2.6.6.3. By Drug Type
      • 5.2.6.6.4. By Therapeutic Area
      • 5.2.6.6.5. By End User
      • 5.2.6.7. Russia
      • 5.2.6.7.1. By Type
      • 5.2.6.7.2. By Process
      • 5.2.6.7.3. By Drug Type
      • 5.2.6.7.4. By Therapeutic Area
      • 5.2.6.7.5. By End User
      • 5.2.6.8. The Netherlands
      • 5.2.6.8.1. By Type
      • 5.2.6.8.2. By Process
      • 5.2.6.8.3. By Drug Type
      • 5.2.6.8.4. By Therapeutic Area
      • 5.2.6.8.5. By End User
      • 5.2.6.9. Rest of Europe
      • 5.2.6.9.1. By Type
      • 5.2.6.9.2. By Process
      • 5.2.6.9.3. By Drug Type
      • 5.2.6.9.4. By Therapeutic Area
      • 5.2.6.9.5. By End User

6. Asia-Pacific Drug Discovery Services Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Process
    • 6.2.3. By Drug Type
    • 6.2.4. By Therapeutic Area
    • 6.2.5. By End User
    • 6.2.6. By Country
      • 6.2.6.1. China
      • 6.2.6.1.1. By Type
      • 6.2.6.1.2. By Process
      • 6.2.6.1.3. By Drug Type
      • 6.2.6.1.4. By Therapeutic Area
      • 6.2.6.1.5. By End User
      • 6.2.6.2. India
      • 6.2.6.2.1. By Type
      • 6.2.6.2.2. By Process
      • 6.2.6.2.3. By Drug Type
      • 6.2.6.2.4. By Therapeutic Area
      • 6.2.6.2.5. By End User
      • 6.2.6.3. Japan
      • 6.2.6.3.1. By Type
      • 6.2.6.3.2. By Process
      • 6.2.6.3.3. By Drug Type
      • 6.2.6.3.4. By Therapeutic Area
      • 6.2.6.3.5. By End User
      • 6.2.6.4. South Korea
      • 6.2.6.4.1. By Type
      • 6.2.6.4.2. By Process
      • 6.2.6.4.3. By Drug Type
      • 6.2.6.4.4. By Therapeutic Area
      • 6.2.6.4.5. By End User
      • 6.2.6.5. Australia & New Zealand
      • 6.2.6.5.1. By Type
      • 6.2.6.5.2. By Process
      • 6.2.6.5.3. By Drug Type
      • 6.2.6.5.4. By Therapeutic Area
      • 6.2.6.5.5. By End User
      • 6.2.6.6. Indonesia
      • 6.2.6.6.1. By Type
      • 6.2.6.6.2. By Process
      • 6.2.6.6.3. By Drug Type
      • 6.2.6.6.4. By Therapeutic Area
      • 6.2.6.6.5. By End User
      • 6.2.6.7. Malaysia
      • 6.2.6.7.1. By Type
      • 6.2.6.7.2. By Process
      • 6.2.6.7.3. By Drug Type
      • 6.2.6.7.4. By Therapeutic Area
      • 6.2.6.7.5. By End User
      • 6.2.6.8. Singapore
      • 6.2.6.8.1. By Type
      • 6.2.6.8.2. By Process
      • 6.2.6.8.3. By Drug Type
      • 6.2.6.8.4. By Therapeutic Area
      • 6.2.6.8.5. By End User
      • 6.2.6.9. Vietnam
      • 6.2.6.9.1. By Type
      • 6.2.6.9.2. By Process
      • 6.2.6.9.3. By Drug Type
      • 6.2.6.9.4. By Therapeutic Area
      • 6.2.6.9.5. By End User
      • 6.2.6.10. Rest of APAC
      • 6.2.6.10.1. By Type
      • 6.2.6.10.2. By Process
      • 6.2.6.10.3. By Drug Type
      • 6.2.6.10.4. By Therapeutic Area
      • 6.2.6.10.5. By End User

7. Latin America Drug Discovery Services Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Process
    • 7.2.3. By Drug Type
    • 7.2.4. By Therapeutic Area
    • 7.2.5. By End User
    • 7.2.6. By Country
      • 7.2.6.1. Brazil
      • 7.2.6.1.1. By Type
      • 7.2.6.1.2. By Process
      • 7.2.6.1.3. By Drug Type
      • 7.2.6.1.4. By Therapeutic Area
      • 7.2.6.1.5. By End User
      • 7.2.6.2. Mexico
      • 7.2.6.2.1. By Type
      • 7.2.6.2.2. By Process
      • 7.2.6.2.3. By Drug Type
      • 7.2.6.2.4. By Therapeutic Area
      • 7.2.6.2.5. By End User
      • 7.2.6.3. Argentina
      • 7.2.6.3.1. By Type
      • 7.2.6.3.2. By Process
      • 7.2.6.3.3. By Drug Type
      • 7.2.6.3.4. By Therapeutic Area
      • 7.2.6.3.5. By End User
      • 7.2.6.4. Peru
      • 7.2.6.4.1. By Type
      • 7.2.6.4.2. By Process
      • 7.2.6.4.3. By Drug Type
      • 7.2.6.4.4. By Therapeutic Area
      • 7.2.6.4.5. By End User
      • 7.2.6.5. Rest of Latin America
      • 7.2.6.5.1. By Type
      • 7.2.6.5.2. By Process
      • 7.2.6.5.3. By Drug Type
      • 7.2.6.5.4. By Therapeutic Area
      • 7.2.6.5.5. By End User

8. Middle East & Africa Drug Discovery Services Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Process
    • 8.2.3. By Drug Type
    • 8.2.4. By Therapeutic Area
    • 8.2.5. By End User
    • 8.2.6. By Country
      • 8.2.6.1. Saudi Arabia
      • 8.2.6.1.1. By Type
      • 8.2.6.1.2. By Process
      • 8.2.6.1.3. By Drug Type
      • 8.2.6.1.4. By Therapeutic Area
      • 8.2.6.1.5. By End User
      • 8.2.6.2. UAE
      • 8.2.6.2.1. By Type
      • 8.2.6.2.2. By Process
      • 8.2.6.2.3. By Drug Type
      • 8.2.6.2.4. By Therapeutic Area
      • 8.2.6.2.5. By End User
      • 8.2.6.3. Qatar
      • 8.2.6.3.1. By Type
      • 8.2.6.3.2. By Process
      • 8.2.6.3.3. By Drug Type
      • 8.2.6.3.4. By Therapeutic Area
      • 8.2.6.3.5. By End User
      • 8.2.6.4. Kuwait
      • 8.2.6.4.1. By Type
      • 8.2.6.4.2. By Process
      • 8.2.6.4.3. By Drug Type
      • 8.2.6.4.4. By Therapeutic Area
      • 8.2.6.4.5. By End User
      • 8.2.6.5. South Africa
      • 8.2.6.5.1. By Type
      • 8.2.6.5.2. By Process
      • 8.2.6.5.3. By Drug Type
      • 8.2.6.5.4. By Therapeutic Area
      • 8.2.6.5.5. By End User
      • 8.2.6.6. Nigeria
      • 8.2.6.6.1. By Type
      • 8.2.6.6.2. By Process
      • 8.2.6.6.3. By Drug Type
      • 8.2.6.6.4. By Therapeutic Area
      • 8.2.6.6.5. By End User
      • 8.2.6.7. Algeria
      • 8.2.6.7.1. By Type
      • 8.2.6.7.2. By Process
      • 8.2.6.7.3. By Drug Type
      • 8.2.6.7.4. By Therapeutic Area
      • 8.2.6.7.5. By End User
      • 8.2.6.8. Rest of MEA
      • 8.2.6.8.1. By Type
      • 8.2.6.8.2. By Process
      • 8.2.6.8.3. By Drug Type
      • 8.2.6.8.4. By Therapeutic Area
      • 8.2.6.8.5. By End User

9. Competitive Landscape

  • 9.1. List of Key Players and Their Offerings
  • 9.2. Global Drug Discovery Services Company Market Share Analysis, 2022
  • 9.3. Competitive Benchmarking, By Operating Parameters
  • 9.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)

10. Impact of Covid-19 on Global Drug Discovery Services Market

11. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 11.1. General Electric
  • 11.2. Eurofins Scientific
  • 11.3. Syngene International Limited
  • 11.4. Wuxi AppTec
  • 11.5. Frontage Labs
  • 11.6. Domainex
  • 11.7. WIL Research Laboratories LLC
  • 11.8. Shanghai Medicilon, Inc.
  • 11.9. Labcorp Drug Development
  • 11.10. Jubilant Biosys Ltd.
  • 11.11. Evotec
  • 11.12. Shanghai ChemPartner
  • 11.13. Charles River Laboratories
  • 11.14. Merck & Co. Inc.
  • 11.15. Thermo Fisher Scientific Inc.
  • 11.16. Other Prominent Players

12. Key Strategic Recommendations

13. Research Methodology

  • 13.1. Qualitative Research
    • 13.1.1. Primary & Secondary Research
  • 13.2. Quantitative Research
  • 13.3. Market Breakdown & Data Triangulation
    • 13.3.1. Secondary Research
    • 13.3.2. Primary Research
  • 13.4. Breakdown of Primary Research Respondents, By Region
  • 13.5. Assumptions & Limitations